Adverse-Event Reporting Failure Leads To Guilty Plea For Olympus, Exec
Executive Summary
Olympus Medical Systems and a former senior executive have pleaded guilty to allegations that they sold duodenoscopes even after failing to submit required adverse-event reports on them.
You may also be interested in...
No Prison Time For Former Olympus Exec In Scope Case
A former Olympus exec who took personal responsibility for the company’s failure to submit duodenoscope-related adverse event reports has been sentenced to one year’s probation and a $5,000 fine.
US FDA Report Confirms Duodenoscope Contamination Risk
An early look at the results of post-market studies that had been ordered by US FDA for duodenoscopes highlights ongoing sterilization issues.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.